World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
72
Citations
21762
World Ranking
19800
National Ranking
9861

Morton Coleman publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Morton Coleman sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 443 publications — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Morton Coleman D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Morton Coleman sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 72 D-Index — 2nd percentile

2% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Morton Coleman is affiliated with Cornell University in the United States and has contributed extensively to the field of medicine, particularly focusing on pathology and forensic medicine, genetics, oncology, molecular biology, and hematology. Their research work consists of 86 publications primarily within these areas.

The scientist's research topics mainly cover lymphoma diagnosis and treatment, chronic lymphocytic leukemia research, viral-associated cancers and disorders, multiple myeloma research and treatments, gastrointestinal tumor research and treatment, colorectal cancer treatments and studies, and lung cancer treatments and mutations.

Recent papers authored or co-authored by Morton Coleman include:

  • Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia, 2021, Haematologica
  • Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis, 2020, Blood Advances
  • Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202), 2020, Leukemia & lymphoma/Leukemia and lymphoma
  • Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patients, 2021, Blood Advances
  • A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma, 2022, British Journal of Haematology

Morton Coleman's frequent co-authors include Abdulraheem Yacoub, Frederick Lansigan, Jason M. Melear, Mecide Gharibo, and David Andorsky. These collaborations have contributed to a number of studies, enhancing the breadth of research in hematology and oncology.

Frequent publication venues where Morton Coleman's work appears include:

  • Blood
  • Hematology Transfusion and Cell Therapy
  • Hematological Oncology
  • Blood Advances
  • Journal of Clinical Oncology

The primary fields of study for Morton Coleman are medicine with a strong focus on subfields such as pathology and forensic medicine, genetics, oncology, molecular biology, and hematology. The main topics addressed throughout their work encompass a wide range of cancer research areas, with particular focus on lymphomas and chronic lymphocytic leukemia.

Best Publications

  • Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Ian W. Flinn

  • Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Jan A. Burger

  • Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

    Susan O'Brien;Richard R Furman;Steven E Coutre;Jeff P Sharman

  • A clinical study of the lupus anticoagulant

    Michael A. Schleider;Ralph L. Nachman;Eric A. Jaffe;Morton Coleman

  • PET Predicts Prognosis After 1 Cycle of Chemotherapy in Aggressive Lymphoma and Hodgkin’s Disease

    Lale Kostakoglu;Morton Coleman;John P. Leonard;Ichiei Kuji

  • Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma

    Peter Martin;Amy Chadburn;Paul Christos;Karen Weil

  • Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

    Jia Ruan;Peter Martin;Richard R. Furman;Shing M. Lee

  • Persistent and relapsing babesiosis in immunocompromised patients.

    Peter J. Krause;Benjamin E. Gewurz;Benjamin E. Gewurz;David Hill;Francisco M. Marty

  • Ibrutinib Resistance in Chronic Lymphocytic Leukemia

    Richard R. Furman;Shuhua Cheng;Pin Lu;Menu Setty

  • Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

    John P. Leonard;Morton Coleman;Jamie C. Ketas;Amy Chadburn

  • Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkin’s Lymphomas

    Richard I. Fisher;Mark S. Kaminski;Richard L. Wahl;Susan J. Knox

  • Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome.

    K Stam;N Heisterkamp;G Grosveld;A de Klein

  • Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin’s Lymphoma

    John P. Leonard;Morton Coleman;Jamie C. Ketas;Amy Chadburn

  • The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.

    Andrea Gallamini;Sally F. Barrington;Alberto Biggi;Stephane Chauvie

  • Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.

    Lale Kostakoglu;John P. Leonard;John P. Leonard;Ichiei Kuji;Morton Coleman;Morton Coleman

  • Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.

    Ariela Noy;Ariela Noy;Sven de Vos;Catherine Thieblemont;Peter Martin

  • Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen.

    Jeffrey Laurence;Morton Coleman;Steven L. Allen;Richard T. Silver

  • BiRD (Biaxin®[clarithromycin]/Revlimid®[lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma

    Ruben Niesvizky;David S. Jayabalan;Paul J. Christos;Jessica R. Furst

  • Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.

    Jia Ruan;Peter Martin;Bijal Shah;Stephen J. Schuster

  • Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma

    John P. Leonard;Morton Coleman;Jamie Ketas;Michelle Ashe

Frequent Co-Authors

John P. Leonard
John P. Leonard Cornell University
Richard R. Furman
Richard R. Furman NewYork–Presbyterian Hospital
Richard T. Silver
Richard T. Silver Cornell University
Selina Chen-Kiang
Selina Chen-Kiang Cornell University
Paul J. Christos
Paul J. Christos Cornell University
Stanley J. Goldsmith
Stanley J. Goldsmith Cornell University
Anne J. Novak
Anne J. Novak Mayo Clinic
David M. Goldenberg
David M. Goldenberg Immunomedics (United States)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in broadening your options within healthcare? There are several affordable and flexible online degrees that can help you enter or advance in key medical fields. If you’re aiming for advanced clinical practice, exploring cheap dnp online programs can be a cost-effective way to earn a Doctor of Nursing Practice and boost your career prospects.

For those drawn to pharmaceuticals, accredited online pathways such as pharmacy school online accredited programs make it possible to study pharmacy without relocating—offering a practical route into this high-demand sector.

Not all healthcare roles are patient-facing. If you have an interest in informatics or management, a health information management bachelor degree online can open doors to essential administrative and data-driven positions in hospitals and clinics.

Meanwhile, certification in fields like medical coding certification is ideal for those seeking a specialized role in medical billing or coding, with flexible learning options to fit any schedule.

Best Scientists Citing Morton Coleman

Trending Scientists

Recently Published Articles